Amiodarone Hydrochloride
FDA-approved product (tablet, oral), marketed as Amiodarone Hydrochloride, Cordarone, Nexterone and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiac arrhythmia
- Ventricular arrhythmia
- Ventricular fibrillation
- Ventricular tachycardia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antiarrhythmics, class iii
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Amiodarone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation
NCT00392431 · start 2003-01
Registered record
- Registry ID
- NCT00392431
- Conditions
- Persistant Atrial Fibrillation
- Interventions
- amiodarone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2003-01
- Completion
- 2007-03
- Enrolment
- 220
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPersistant Atrial FibrillationInterventionamiodaronePhaseNot applicableRegistry statusCompletedRadiofrequency Catheter Ablation for Chronic Atrial Fibrillation
NCT00272636 · start 2002-11
Registered record
- Registry ID
- NCT00272636
- Conditions
- Atrial Fibrillation
- Interventions
- Radiofrequency catheter ablation; Amiodarone and cardioversion
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-11
- Completion
- 2005-02
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionRadiofrequency catheter ablation; Amiodarone and cardioversionPhaseNot applicableRegistry statusCompletedAmiodarone to Prevent Post-Operative Arrhythmias
NCT00251706 · start 1999-02
Registered record
- Registry ID
- NCT00251706
- Conditions
- Atrial Fibrillation
- Interventions
- amiodarone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-02
- Completion
- 2004-09
- Enrolment
- 600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionamiodaronePhasePhase 3Registry statusCompletedSudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
NCT00000609 · start 1997-05
Registered record
- Registry ID
- NCT00000609
- Conditions
- Arrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases; Heart Failure, Congestive; Heart Failure
- Interventions
- amiodarone; defibrillators, implantable
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1997-05
- Completion
- 2005-04
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases +2 moreInterventionamiodarone; defibrillators, implantablePhasePhase 3Registry statusCompletedAtrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
NCT00000556 · start 1995-03
Registered record
- Registry ID
- NCT00000556
- Conditions
- Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
- Interventions
- amiodarone; sotalol; propafenone; flecainide; quinidine; moricizine; disopyramide; procainamide; adrenergic beta antagonists; verapamil; diltiazem; digoxin; catheter ablation; pacemaker, artificial
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1995-03
- Completion
- 2002-09
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart DiseasesInterventionamiodarone; sotalol; propafenone; flecainide +10 morePhasePhase 3Registry statusCompleted